300791.CS5
Sirio Pharma H1 revenue hits 2.052 billion yuan as global operating capabilities continue to improve
Sirio Pharma disclosed its 2026 semi-annual report, with first-half operating revenue reaching 2.052 billion yuan, up 0.51 percent year on year. By region, China revenue was 802 million yuan, down 2.02 percent year on year, while gross margin improved by 0.73 percentage points. Europe revenue was 402 million yuan, up 11.74 percent year on year, with gross margin up 1.74 percentage points. Asia-Pacific and other regions revenue was 195 million yuan, up 86.79 percent year on year, driven by deeper cooperation with clients in Australia and New Zealand and higher softgel volumes. Americas revenue was 654 million yuan, down 13.93 percent year on year, mainly affected by US tariff policy, though gross margin improved by 2.42 percentage points. The company has completed the sale of core assets in its personal care business to focus on its core nutrition and health operations. The second gummy production line at its US plant has begun operations, and construction of its Thailand production base is advancing.
300791.CS · Capital · Neutral H1 revenue up 0.51% with mixed regional performance; US tariffs hurt Americas revenue but margins improved, and asset sale focuses on core business.